Explore more publications!
Health Update Bahamas
Got News to Share?

Health Update Bahamas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Update Bahamas.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 19, 2025

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
December 19, 2025

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

Indeterminate GlobeNewswire
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
December 19, 2025

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

Indeterminate GlobeNewswire
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
December 19, 2025

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

Indeterminate GlobeNewswire
Glass House Brands Applauds Cannabis Reform Action
December 19, 2025

Glass House Brands Applauds Cannabis Reform Action

Indeterminate GlobeNewswire
Cue Biopharma Announces Pricing of $10 Million Public Offering
December 19, 2025

Cue Biopharma Announces Pricing of $10 Million Public Offering

Indeterminate GlobeNewswire
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
December 19, 2025

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Indeterminate GlobeNewswire
Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
December 19, 2025

Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update

Indeterminate GlobeNewswire
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
December 19, 2025

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Indeterminate GlobeNewswire
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
December 19, 2025

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Indeterminate GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
December 19, 2025

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Indeterminate GlobeNewswire
OKYO Pharma to Ring the Opening Bell at Nasdaq
December 19, 2025

OKYO Pharma to Ring the Opening Bell at Nasdaq

Indeterminate GlobeNewswire
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
December 19, 2025

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

Indeterminate GlobeNewswire
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
December 19, 2025

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Indeterminate GlobeNewswire
The Ensign Group, Inc. Increases Quarterly Dividend to $0.0650 Per Share
December 19, 2025

The Ensign Group, Inc. Increases Quarterly Dividend to $0.0650 Per Share

Indeterminate GlobeNewswire
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
December 19, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Indeterminate GlobeNewswire
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
December 19, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Indeterminate GlobeNewswire
Sai Life Sciences Releases Sustainability Report 2024–25
December 19, 2025

Sai Life Sciences Releases Sustainability Report 2024–25

Indeterminate GlobeNewswire
Genenta Science Provides Update on CEO Ownership
December 19, 2025

Genenta Science Provides Update on CEO Ownership

Indeterminate GlobeNewswire
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
December 19, 2025

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions